Company successfully listed on Nasdaq under the symbol “AIFF”Partnered with multiple neuroscience pharmaceutical companies, including Bright ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Analysts have set 12-month price targets for Incyte, revealing an average target of $73.69, a high estimate of $97.00, and a ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

A fireside chat with a Tamika D. Mallory will go down at sunset to inspire attendees. Powered by Novartis, Grow with Google, Chase for Business, and Barbados Tourism Marketing, the Pow(H)er Experience ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

The global neuroendocrine carcinoma treatment market is poised for substantial growth, with revenue expected to reach USD ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00. According to TipRanks, Weston is ranked #1736 out of 9162 analysts ...